Tax1BP1 limits hepatic inflammation and reduces experimental hepatocarcinogenesis.
Animals
Blotting, Western
Carcinogenesis
/ metabolism
Carcinoma, Hepatocellular
/ metabolism
Flow Cytometry
Hepatitis
/ metabolism
Hepatocytes
/ metabolism
Intracellular Signaling Peptides and Proteins
/ metabolism
Kupffer Cells
/ metabolism
Liver
/ metabolism
Liver Neoplasms, Experimental
/ metabolism
Mice
Mice, Inbred C57BL
Mice, Knockout
Microscopy, Confocal
NF-kappa B
/ metabolism
Neoplasm Proteins
/ metabolism
Real-Time Polymerase Chain Reaction
Signal Transduction
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
04
12
2019
accepted:
09
09
2020
entrez:
2
10
2020
pubmed:
3
10
2020
medline:
5
1
2021
Statut:
epublish
Résumé
The nuclear factor kappa beta (NFκB) signaling pathway plays an important role in liver homeostasis and cancer development. Tax1-binding protein 1 (Tax1BP1) is a regulator of the NFκB signaling pathway, but its role in the liver and hepatocellular carcinoma (HCC) is presently unknown. Here we investigated the role of Tax1BP1 in liver cells and murine models of HCC and liver fibrosis. We applied the diethylnitrosamine (DEN) model of experimental hepatocarcinogenesis in Tax1BP1
Identifiants
pubmed: 33004985
doi: 10.1038/s41598-020-73387-4
pii: 10.1038/s41598-020-73387-4
pmc: PMC7530720
doi:
Substances chimiques
Intracellular Signaling Peptides and Proteins
0
NF-kappa B
0
Neoplasm Proteins
0
TAX1BP1 protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16264Références
El-Serag, H. B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264–1273 (2012).
doi: 10.1053/j.gastro.2011.12.061
Sartorius, K., Sartorius, B., Aldous, C., Govender, P. S. & Madiba, T. E. Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol. 39, 284–290 (2015).
doi: 10.1016/j.canep.2015.04.006
Elsharkawy, A. M. & Mann, D. A. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46, 590–597 (2007).
doi: 10.1002/hep.21802
Vainer, G. W., Pikarsky, E. & Ben-Neriah, Y. Contradictory functions of NF-kappaB in liver physiology and cancer. Cancer Lett. 267, 182–188 (2008).
doi: 10.1016/j.canlet.2008.03.016
Pasparakis, M. Regulation of tissue homeostasis by NF-kappaB signalling: Implications for inflammatory diseases. Nat. Rev. Immunol. 9, 778–788 (2009).
doi: 10.1038/nri2655
Pikarsky, E. et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461–466 (2004).
doi: 10.1038/nature02924
Luedde, T. et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11, 119–132 (2007).
doi: 10.1016/j.ccr.2006.12.016
Maeda, S., Kamata, H., Luo, J. L., Leffert, H. & Karin, M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977–990 (2005).
doi: 10.1016/j.cell.2005.04.014
Hayden, M. S. & Ghosh, S. Shared principles in NF-kappaB signaling. Cell 132, 344–362 (2008).
doi: 10.1016/j.cell.2008.01.020
Nenci, A. et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446, 557–561 (2007).
doi: 10.1038/nature05698
Hellerbrand, C. et al. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28, 21–27 (2007).
doi: 10.1093/carcin/bgl081
Urbanik, T. et al. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice. J. Hepatol. 57, 995–1003 (2012).
doi: 10.1016/j.jhep.2012.06.017
De Valck, D. et al. The zinc finger protein A20 interacts with a novel anti-apoptotic protein which is cleaved by specific caspases. Oncogene 18, 4182–4190 (1999).
doi: 10.1038/sj.onc.1202787
Ling, L. & Goeddel, D. V. T6BP, a TRAF6-interacting protein involved in IL-1 signaling. Proc. Natl. Acad. Sci. 97, 9567–9572 (2000).
doi: 10.1073/pnas.170279097
Iha, H. et al. Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-kappaB activation. EMBO J. 27, 629–641 (2008).
doi: 10.1038/emboj.2008.5
Shembade, N. et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat. Immunol. 9, 254–262 (2008).
doi: 10.1038/ni1563
Nakano, S. et al. Commensal microbiota contributes to chronic endocarditis in TAX1BP1 deficient mice. PLoS ONE 8, e73205. https://doi.org/10.1371/journal.pone.0073205 (2013).
doi: 10.1371/journal.pone.0073205
pubmed: 24086273
pmcid: 3785488
Tanaka, Y. et al. Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma. J. Hepatol. 49, 746–757 (2008).
doi: 10.1016/j.jhep.2008.06.019
Klingmüller, U. et al. Primary mouse hepatocytes for systems biology approaches: A standardized in vitro system for modelling of signal transduction pathways. Syst. Biol. (Stevenage) 153, 433–447 (2006).
doi: 10.1049/ip-syb:20050067
Froh, M., Konno, A. & Thurman, R. G. Isolation of liver Kupffer cells. Curr. Protoc. Toxicol. 14, 144 (2003).
Olesch, C. et al. MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer. Oncotarget 6, 10284–10296 (2015).
doi: 10.18632/oncotarget.3581
Waidmann, O. et al. Inhibition of the equilibrative nucleoside transporter 1 and activation of A2A adenosine receptors by 8-(4-chlorophenylthio)-modified cAMP analogs and their hydrolytic products. J. Biol. Chem. 284, 32256–32263 (2009).
doi: 10.1074/jbc.M109.056622
Ulrich, M., Seeber, S., Becker, C. M. & Enz, R. Tax1-binding protein 1 is expressed in the retina and interacts with the GABA(C) receptor rho1 subunit. Biochem. J. 401, 429–436 (2007).
doi: 10.1042/BJ20061036
Luedde, T. & Schwabe, R. F. NF-κB in the liver–linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 8, 108–118 (2011).
doi: 10.1038/nrgastro.2010.213
Karin, M. NF-kB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 1, a000141. https://doi.org/10.1101/cshperspect.a000141 (2009).
doi: 10.1101/cshperspect.a000141
pubmed: 20066113
pmcid: 2773649
Seki, E., Brenner, D. A. & Karin, M. A liver full of JNK: Signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 143, 307–320 (2012).
doi: 10.1053/j.gastro.2012.06.004
Shembade, N., Harhaj, N. S., Liebl, D. J. & Harhaj, E. W. Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and LPS-mediated NF-kappaB and JNK signaling. EMBO J. 26, 3910–3922 (2007).
doi: 10.1038/sj.emboj.7601823
Matsushita, N. et al. Regulation of B cell differentiation by the ubiquitin-binding protein TAX1BP1. Sci. Rep. 6, 31266. https://doi.org/10.1038/srep31266 (2016).
doi: 10.1038/srep31266
pubmed: 27515252
pmcid: 4981851
Whang, M. I. et al. The ubiquitin binding protein TAX1BP1 mediates autophagasome induction and the metabolic transition of activated T cells. Immunity 46, 405–420 (2017).
doi: 10.1016/j.immuni.2017.02.018
Yamagishi, M. et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell 21, 121–135 (2012).
doi: 10.1016/j.ccr.2011.12.015
Wu, S. Y. et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat. Commun. 7, 11169. https://doi.org/10.1038/ncomms11169 (2016).
doi: 10.1038/ncomms11169
pubmed: 27041221
pmcid: 4822037
Lian, J. et al. miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma. Oncotarget 7, 2672–2683 (2016).
doi: 10.18632/oncotarget.6603
Zhu, H., Han, C. & Wu, T. MiR-17-92 cluster promotes hepatocarcinogenesis. Carcinogenesis 36, 1213–1222 (2015).
doi: 10.1093/carcin/bgv112
Liu, P. et al. Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J. Hepatol. 37, 63–71 (2002).
doi: 10.1016/S0168-8278(02)00064-8
Sakurai, T., Maeda, S., Chang, L. & Karin, M. Loss of hepatic NF-k B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. 103, 10544–10551 (2006).
doi: 10.1073/pnas.0603499103
Parvatiyar, K., Barber, G. N. & Harhaj, E. W. TAX1BP1 and A20 inhibit antiviral signaling by targeting TBK1-IKKi kinases. J. Biol. Chem. 285, 14999–15009 (2010).
doi: 10.1074/jbc.M110.109819
Vilasco, M. et al. The protein kinase IKKepsilon can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV-infected livers. Hepatology 44, 1635–1647 (2006).
doi: 10.1002/hep.21432